Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia.

Yu L, Liu C, Vandeusen J, Becknell B, Dai Z, Wu YZ, Raval A, Liu TH, Ding W, Mao C, Liu S, Smith LT, Lee S, Rassenti L, Marcucci G, Byrd J, Caligiuri MA, Plass C.

Nat Genet. 2005 Mar;37(3):265-74.

2.

A NotI-EcoRV promoter library for studies of genetic and epigenetic alterations in mouse models of human malignancies.

Yu L, Liu C, Bennett K, Wu YZ, Dai Z, Vandeusen J, Opavsky R, Raval A, Trikha P, Rodriguez B, Becknell B, Mao C, Lee S, Davuluri RV, Leone G, Van den Veyver IB, Caligiuri MA, Plass C.

Genomics. 2004 Oct;84(4):647-60.

PMID:
15475242
3.

Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer.

Umetani N, Mori T, Koyanagi K, Shinozaki M, Kim J, Giuliano AE, Hoon DS.

Oncogene. 2005 Jul 7;24(29):4721-7.

PMID:
15897910
4.

A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors.

Fraga MF, Herranz M, Espada J, Ballestar E, Paz MF, Ropero S, Erkek E, Bozdogan O, Peinado H, Niveleau A, Mao JH, Balmain A, Cano A, Esteller M.

Cancer Res. 2004 Aug 15;64(16):5527-34.

5.

Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer.

Noetzel E, Veeck J, Niederacher D, Galm O, Horn F, Hartmann A, Knüchel R, Dahl E.

BMC Cancer. 2008 May 30;8:154. doi: 10.1186/1471-2407-8-154.

6.

Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia.

Taylor KH, Pena-Hernandez KE, Davis JW, Arthur GL, Duff DJ, Shi H, Rahmatpanah FB, Sjahputera O, Caldwell CW.

Cancer Res. 2007 Mar 15;67(6):2617-25.

7.

[Promoter methylation of ID4. A marker for recurrence-free survival in human breast cancer].

Noetzel E, Veeck J, Horn F, Hartmann A, Knüchel R, Dahl E.

Pathologe. 2008 Nov;29 Suppl 2:319-27. doi: 10.1007/s00292-008-1038-7. German.

PMID:
18807039
8.

Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancer.

Carey JP, Asirvatham AJ, Galm O, Ghogomu TA, Chaudhary J.

BMC Cancer. 2009 Jun 7;9:173. doi: 10.1186/1471-2407-9-173.

9.

Rapid and sensitive detection of CpG-methylation using methyl-binding (MB)-PCR.

Gebhard C, Schwarzfischer L, Pham TH, Andreesen R, Mackensen A, Rehli M.

Nucleic Acids Res. 2006 Jul 5;34(11):e82.

10.

[Id4 gene methylation for detection of minimal residual disease in acute leukemia].

Zhao Y, Yu L, Wang QS, Li HH, Bo J, Wang SH, Jin HJ, Lou FD.

Zhonghua Xue Ye Xue Za Zhi. 2006 May;27(5):298-301. Chinese.

PMID:
16875575
11.

Promoter methylation study of the H37/RBM5 tumor suppressor gene from the 3p21.3 human lung cancer tumor suppressor locus.

Oh JJ, Boctor BN, Jimenez CA, Lopez R, Koegel AK, Taschereau EO, Phan DT, Jacobsen SE, Slamon DJ.

Hum Genet. 2008 Feb;123(1):55-64.

PMID:
18038152
12.

Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers.

Sakakura C, Hasegawa K, Miyagawa K, Nakashima S, Yoshikawa T, Kin S, Nakase Y, Yazumi S, Yamagishi H, Okanoue T, Chiba T, Hagiwara A.

Clin Cancer Res. 2005 Sep 15;11(18):6479-88.

13.

Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.

Hoque MO, Begum S, Topaloglu O, Chatterjee A, Rosenbaum E, Van Criekinge W, Westra WH, Schoenberg M, Zahurak M, Goodman SN, Sidransky D.

J Natl Cancer Inst. 2006 Jul 19;98(14):996-1004.

14.

Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.

Veeck J, Bektas N, Hartmann A, Kristiansen G, Heindrichs U, Knüchel R, Dahl E.

Breast Cancer Res. 2008;10(5):R82. doi: 10.1186/bcr2151.

15.

Epigenetic regulation of the human retinoblastoma tumor suppressor gene promoter by CTCF.

De La Rosa-Velázquez IA, Rincón-Arano H, Benítez-Bribiesca L, Recillas-Targa F.

Cancer Res. 2007 Mar 15;67(6):2577-85.

16.

Frequent DNA methylation but not mutation of the ID4 gene in malignant lymphoma.

Hagiwara K, Nagai H, Li Y, Ohashi H, Hotta T, Saito H.

J Clin Exp Hematop. 2007 Apr;47(1):15-8.

17.

HOP/OB1/NECC1 promoter DNA is frequently hypermethylated and involved in tumorigenic ability in esophageal squamous cell carcinoma.

Yamashita K, Kim MS, Park HL, Tokumaru Y, Osada M, Inoue H, Mori M, Sidransky D.

Mol Cancer Res. 2008 Jan;6(1):31-41. doi: 10.1158/1541-7786.MCR-07-0213.

18.

Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers.

Koga Y, Kitajima Y, Miyoshi A, Sato K, Kitahara K, Soejima H, Miyazaki K.

Ann Surg Oncol. 2005 May;12(5):354-63.

PMID:
15915369
19.

[Aberrant promoter methylation of tumor suppressor genes in serum from lung cancer patients: frequency and correlation with clinicopathological characteristics].

Zemaitis M, Rieger N, Fischer JR, Sakalauskas R, Malakauskas K, Lahm H.

Medicina (Kaunas). 2005;41(2):123-31. Lithuanian.

20.

Gene silencing by DNA methylation in haematological malignancies.

Boultwood J, Wainscoat JS.

Br J Haematol. 2007 Jul;138(1):3-11. Review.

PMID:
17489980
Items per page

Supplemental Content

Support Center